The following represents disclosure information provided by authors of this abstract. The Genitourinary Cancers Symposium Program Committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered self-held and compensated unless otherwise noted. Employment/Leadership relationships are considered compensated employment unless otherwise noted. L = Leadership, U = Uncompensated, I = Immediate Family Member, B = Both Myself and Immediate Family Member, Inst = My Institution
Feasibility of continuing docetaxel-based therapy in patients with metastatic castrate-resistant prostate cancer (mCRPC) that experience hypersensitivity reactions (HSR).
Anna Couvillon
No relevant relationships to disclose
Melony A. Beatson
No relevant relationships to disclose
Nancy Harold
No relevant relationships to disclose
Fatima H. Karzai
No relevant relationships to disclose
Ravi Amrit Madan
No relevant relationships to disclose
James L. Gulley
No relevant relationships to disclose
William L. Dahut
No relevant relationships to disclose